MacroGenics disclosed today (July 1, 2026) that board member Dr. Karen Ferrante has resigned for personal reasons, effective September 1, 2026. The company emphasized that her departure is not related to any disagreement with the company's operations, policies, or practices, and thanked her for her contributions.

View Full Filing (SEC EDGAR)

2026-07-07

MacroGenics has completed the sale of its GMP manufacturing and CDMO operations to Bora Pharmaceuticals for $122.5 million before fees. The deal closed on June 30, 2026, and includes assets in Maryland.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding MACROGENICS INC (MGNX)?

Major stakeholders currently include Armistice Capital, LLC ($17.4M), Renaissance Technologies LLC ($8.6M), Millennium Management LLC ($8.1M). Based on the latest 13F filings, there are a total of 108 tracked investment funds and institutions maintaining positions in MGNX.

What is the overall institutional sentiment toward MGNX recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $60.9M, driven by 56 managers accumulating shares while 38 reduced their exposure.

Which institutions have been selling or reducing their MGNX positions?

In the latest period, 28 funds trimmed their holdings, and 10 managers completely exited their positions. The aggregate reported sell value was $28.2M.

Are there any notable investors adding MGNX to their portfolios?

Yes, buying activity remains notable. 28 institutions opened new positions in {ticker}, and 28 existing holders added to their shares. The total reported buy value for the quarter amounted to $76.8M.